This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2005 by Beth Israel Deaconess Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Beth Israel Deaconess Medical Center Identifier:
First received: August 25, 2005
Last updated: December 19, 2007
Last verified: August 2005
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.

Hepatitis C

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects

Resource links provided by NLM:

Further study details as provided by Beth Israel Deaconess Medical Center:

Estimated Enrollment: 26
Study Start Date: March 2004
Estimated Study Completion Date: December 2006
Detailed Description:

Subjects with non-cirrhotic hepatitis C will have a magnetic resonance imaging (MRI)/magnetic resonance (MR) spectroscopy and neuropsychological testing prior to starting interferon. Subjects will have repeat testing following 12 weeks of interferon therapy and again at 12 weeks post interferon therapy.

MR spectroscopy (MRS) will measure the cerebral metabolites, NAA (N-acetyl aspartate), Cho (choline), MI (myoinositol) and Cr (creatine) at 3 distinct brain regions, i.e. basal ganglia and 2 locations within the frontal cortex.

Neuropsychological testing will include tests of the following cognitive domains: executive functioning, memory, language, motor skills and will also include questionnaires pertaining to quality of life (SF-36), mood (Beck's depression inventory) and a self-rating cognitive questionnaire (Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scales [CAARS]).

Control subjects will include non-cirrhotic HCV subjects who are not taking interferon therapy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (>18 years old) of both sexes with chronic HCV infection (all genotypes).
  • Subjects due to start treatment with pegylated interferon-alpha (IFN-a) for HCV eradication.
  • Subjects with chronic hepatitis C who have elected not to be treated with pegylated-IFN-a
  • Subjects with mild fibrosis on liver biopsy (stage 0-III/IV fibrosis)
  • Subjects able to give informed consent.
  • Subjects with controlled depression currently taking anti-depressant medication.

Exclusion Criteria:

  • Subjects with cirrhosis on liver biopsy.
  • Subjects with active alcohol or drug abuse.
  • Subjects co-infected with human immunodeficiency virus (HIV).
  • Subjects with structural brain abnormality, past history of cerebrovascular accident (CVA) or serious head trauma.
  • Subjects with seizure disorder.
  • Subjects with any contraindication to IFN therapy.
  • Subjects with a poor command of the English language.
  • Subjects with a contraindication to MRI, e.g. pacemaker, claustrophobia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00136214

Contact: Valerie Byrnes, MD 617 632 1070

United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Valerie Byrnes, MD    617-632-1070   
Principal Investigator: Nezam Afdhal, MD         
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Principal Investigator: Nezam Afdhal, MD Beth Israel Deaconess Medical Center
  More Information Identifier: NCT00136214     History of Changes
Other Study ID Numbers: 2003P-000341
Study First Received: August 25, 2005
Last Updated: December 19, 2007

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents processed this record on September 19, 2017